HER2-låg bröstcancer ny entitet : ökar behandlingsmöjligheterna

• Breast cancer is the most common form of cancer among women in Sweden. Several decades ago it was recognized that the Human epidermal growth factor receptor 2 (HER2) is involved in a critical growth system for breast cancer cells. Overexpression of HER2 (immunohistochemistry [IHC] 2+/3+, in situ hybridization [ISH] positive) is present in 15 percent of all breast cancers.HER2-low breast cancer has been discovered as a separate entity; the most commonly used definition so far is IHC 1+/2+ and ISH negative, but general consensus is still lacking. Clinical studies with the HER2 antibody drug conjugate trastuzumab deruxtecan (Enhertu) have shown impressive antitumor activity among women with advanced HER2-low breast cancer and this is expected to become part of routine treatment in the near future. Research is needed to establish refined ways to define HER2-low breast cancer, and a possible role lies in new imaging methods such as HER2 positron emission tomography (PET) with a [68Ga]Ga-ABY-025 tracer.

• Överuttryck av HER2 (human epidermal growth factor receptor 2) (immunohistokemi [IHC] 2+/3+ eller in situ-hybridisering [ISH]-positiv) finns i ca 15 procent av bröstcancerfall.HER2-låg bröstcancer har upptäckts vara en separat entitet, som utgör ca 50 procent av fallen. Definitionen som används mest är IHC 1+/2+ eller ISH-negativ.Studier med HER2-antikroppsläkemedelskonjugatet trastuzumab–deruxtekan (Enhertu) har visat imponerande antitumoral aktivitet hos kvinnor med icke-re­sekabel HER2-låg bröstcancer.Forskning behövs för att komma fram till förfinade sätt att definiera HER2-låg bröstcancer, och en möjlig roll finns hos nya avbildningsmetoder, som HER2-positron­emissiontomografi (PET) med [68Ga]Ga-ABY-025.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publication and Content Type

ref (subject category)

for (subject category)